Cited 13 times in
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범경 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-09-29T01:02:59Z | - |
dc.date.available | 2021-09-29T01:02:59Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0953-6205 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184163 | - |
dc.description.abstract | Background & aims: Whether chronic hepatitis B (CHB) patients during immune-tolerant (IT) phase are at low risk of hepatocellular carcinoma (HCC) is still controversial. We performed a multicenter study to determine their long-term prognosis. Methods: Untreated IT group included patients < 40 years of age, with persistently hepatitis B e antigen [HBeAg] positivity, serum HBV-DNA>6 log10IU/mL, and ALT level < 40 U/L, using age and HBV-DNA criteria by the American Association for the Study of Liver Diseases (AASLD) guideline. Cumulative HCC risk of untreated IT group (n=194) was compared to HBeAg-positive patients undergoing antiviral therapy according to the practice and reimbursement guidelines (treated HBeAg[+] group, n=454). Patients with history of cirrhosis or HCC at baseline were excluded. Results: During follow-up (median 62.1 months), HCC did not develop in any patient among untreated IT group, whereas the cumulative probability of HCC at 3, 5, and 9 years in the treated HBeAg(+) group was 0.5%, 0.7%, and 1.3%, respectively (p=0.203). Ninety-seven patients among untreated IT group entered immune-active phase, of whom 86 (88.7%) started antiviral treatment. A high normal ALT level (20-39 U/L) was associated with an increased risk of a phase change, compared to ALT < 20 U/L. After censoring at the time of phase change, the cumulative HCC risk was also not significantly different between two groups (p=0.258). Conclusions: No actual HCC risk during untreated IT phase defined by age and HBV-DNA criteria of the AASLD guideline exists, supporting their diagnostic validity from the perspective of long-term prognosis. Further validation studies are required. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents / therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / epidemiology | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Hepatitis B e Antigens | - |
dc.subject.MESH | Hepatitis B virus / genetics | - |
dc.subject.MESH | Hepatitis B, Chronic* / complications | - |
dc.subject.MESH | Hepatitis B, Chronic* / drug therapy | - |
dc.subject.MESH | Hepatitis B, Chronic* / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms* / epidemiology | - |
dc.title | Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Young Eun Chon | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Terry Cheuk-Fung Yip | - |
dc.contributor.googleauthor | Yee-Kit Tse | - |
dc.contributor.googleauthor | Grace Lai-Hung Wong | - |
dc.contributor.googleauthor | Vincent Wai-Sun Wong | - |
dc.contributor.googleauthor | Henry Lik-Yuen Chan | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.identifier.doi | 10.1016/j.ejim.2020.10.022 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J00828 | - |
dc.identifier.eissn | 1879-0828 | - |
dc.identifier.pmid | 33288393 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0953620520304088 | - |
dc.subject.keyword | Antiviral therapy | - |
dc.subject.keyword | Hepatitis B e antigen | - |
dc.subject.keyword | Hepatitis B virus | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Immune-tolerant | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 84 | - |
dc.citation.startPage | 68 | - |
dc.citation.endPage | 73 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF INTERNAL MEDICINE, Vol.84 : 68-73, 2021-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.